Peyton Anderson Cancer Center Navicent Health

The Peyton Anderson Cancer Center is located at 800 First Street, Macon, Georgia. Visitors to the Peyton Anderson Health Center will find warm, friendly staff providing patient focused care.

Everything about us is all about you.

 

Among the services you will find at The Peyton Anderson Cancer Center, Navicent Health are:

  • PET/CT Center,Navicent Health
  • Breast Care Center, Navicent Health
  • Central Georgia Cancer Care
  • Infusion Services, Navicent Health
  • Central Georgia Radiation Oncology
  • Surgical Oncology
  • Gynecologic Oncology
  • Genetic Counselor
  • Navigators
  • Reading Room
  • Meditation Room

 

 

Treatment Sites in Georgia

Primary Location

800 1st Street
Macon, GA 31201
478-633-2152 (p)
478-633-8894 (f)
www.navicenthealth.org

driving directions


Central Georgia Cancer Care

800 First Street
Suite 410
Macon, 31201
478 633-2152 (p)
(478) 633-8894 (f)


driving directions


Central Georgia Cancer Care

114 Sutherlin Drive
Suite C-1
Warner Robins, 31088
(478) 633-2152 (p)
(478) 633-8894 (f)


driving directions

Clinical Trials in Georgia

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: Andrew Weatherall - (478) 633-2152


A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Cancer Type: Prostate Cancer
Study Coordinator: Kristin Spradlin - (478) 633-1738


A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: Andrew Weatherall - (478) 633-2152


A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Cancer Type: Bladder Cancer
Study Coordinator: Kristin Spradlin - (478) 633-1738


A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients with Residual Triple-Negative Basal-like Breast Cancer following Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: Andrew Weatherall - (478) 633-2152


A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients With Hormone Receptor-Positive Advanced Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Andrew Weatherall - (478)633-2152


Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer
Study Coordinator: Andrew Weatherall - (478)633-2152


EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary

EROS: Engendering Reproductive Health within Oncologic Survivorship
Cancer Type: Unknown Primary

Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer
Cancer Type: Prostate Cancer
Study Coordinator: Andrew Weatherall - 478 633 2152


Phase III Randomized Study of Pazopanib Hydrochloride in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy
Cancer Type: Kidney Cancer
Study Coordinator: Kristin Spradlin - (478) 633-1738


Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer
Study Coordinator: Kristin Spradlin - (478) 633-1738


Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Cancer Type: Breast Cancer
Study Coordinator: Andrew Weatherall - (478) 633-2152


Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Cancer Type: Oral Cancer
Study Coordinator: Kristin Spradlin - 478 633-1738


Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Cancer Type: Breast Cancer

S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Cancer Type: Lung Cancer
Study Coordinator: Andrew Weatherall - (478) 633-2152)